跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

1672206

USP

托吡酯

United States Pharmacopeia (USP) Reference Standard

别名:

2,3: 双-4,5-O-（1-甲基亚乙基）-36--D -吡喃果糖氨基磺酸酯, McN 4853, RWJ 17021, 妥泰

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C12H21NO8S
CAS号:
97240-79-4
分子量:
339.36
MDL编号:
MFCD00865320
UNSPSC代码:
41116107
PubChem化学物质编号:
329751353
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

topiramate

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

NS(OC[C@]12[C@](OC(C)(C)O2)([H])[C@@]3([H])[C@@](OC(C)(C)O3)([H])CO1)(=O)=O

InChI

1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

InChI key

KJADKKWYZYXHBB-XBWDGYHZSA-N

基因信息

human ... CA2(760) , CA4(762) , GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879) , GRIA1(2890) , GRIA2(2891) , GRIA3(2892) , GRIA4(2893) , GRIK1(2897) , GRIK2(2898) , GRIK3(2899) , GRIK4(2900) , GRIK5(2901) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Topiramate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Topiramate Capsules
  • Topiramate Tablets
  • Topiramate Compounded Oral Suspension
Topiramate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Topiramate Tablets
  • Topiramate Compounded Oral Suspension

生化/生理作用

红藻氨酸 GluR5 受体拮抗剂；抗惊厥药。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H315,H319,H335

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Topiramate
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 42(6), 4429-4429 (2020)
Topiramate Compounded Oral Suspension
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(4), 4436-4436 (2014)
Topiramate Capsules
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(1), 4432-4432 (2020)
Topiramate Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 34(5), 4434-4434 (2020)
Gina Cosentino et al.
Drug design, development and therapy, 7, 267-278 (2013-05-01)
Obesity is now a major public health concern worldwide with increasing prevalence and a growing list of comorbidities and complications. The morbidity, mortality and reduced productivity associated with obesity and its complications result in a major burden to health care
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门